Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Marburg, Hessen, Germany.
WIG2 GmbH Scientific Institute for Health Economics and Health System Research, Leipzig, Sachsen, Germany.
Int J Chron Obstruct Pulmon Dis. 2021 Aug 24;16:2407-2417. doi: 10.2147/COPD.S322036. eCollection 2021.
Recent studies evaluating the predictive value of different variables on future exacerbations suggest exacerbation history as the strongest predictor. We examined the effect of exacerbation history on subsequent events in a large sample population with over 250,000 COPD patients using up to 8 years of longitudinal healthcare data from Germany.
Patients 40 years or older with any COPD diagnosis in primary or secondary care were included from 2011 to 2017 (index period) from healthcare insurance claims (Germany; WIG2 research database), with 12 months before index date as baseline and at least 12-month follow-up. Exacerbations during baseline were defined as moderate (treatment with oral corticosteroids or antibiotics, J01AA, J01CA) or severe (emergency visit or hospitalization).
Patients without (category A), with one moderate (category B), or with either one severe or several baseline exacerbations (category C) experienced an average of 0.9 (CI 0.9-0.9), 1.9 (CI 1.9-1.9), and 6.3 (CI 6.1-6.3) exacerbations during the first 3 years of follow-up, respectively. By 8 years, 87.0% (CI 86.6-87.4), 70.5% (CI 69.9-71.0) and 49.1% (CI 48.9-49.3) of category C, B and A patients had experienced a subsequent exacerbation.
Baseline exacerbations increased the likelihood of, and reduced time to subsequent exacerbations. Even patients without baseline exacerbations experienced exacerbations within three years, emphasizing the importance of adequate treatment in patients with less severe disease presentation as well.
最近的研究评估了不同变量对未来恶化的预测价值,结果表明恶化史是最强的预测因素。我们使用德国长达 8 年的纵向医疗保健数据,在一个超过 25 万 COPD 患者的大样本人群中,检查了恶化史对随后事件的影响。
从 2011 年至 2017 年(索引期),从医疗保健保险公司理赔中(德国;WIG2 研究数据库)纳入年龄在 40 岁或以上、有任何 COPD 诊断的患者,索引日期前 12 个月为基线期,至少有 12 个月的随访期。基线期内的恶化定义为中度(口服皮质类固醇或抗生素治疗,J01AA,J01CA)或重度(急诊就诊或住院)。
无(A 类)、有一次中度(B 类)或有一次或多次基线期恶化(C 类)的患者在随访的前 3 年内分别平均经历 0.9(CI 0.9-0.9)、1.9(CI 1.9-1.9)和 6.3(CI 6.1-6.3)次恶化。到第 8 年,87.0%(CI 86.6-87.4)、70.5%(CI 69.9-71.0)和 49.1%(CI 48.9-49.3)的 C、B 和 A 类患者经历了随后的恶化。
基线恶化增加了随后恶化的可能性,并缩短了随后恶化的时间。即使没有基线恶化的患者也在三年内发生了恶化,这强调了在疾病表现较轻的患者中进行充分治疗的重要性。